Myocardial Infarction
Conditions
Keywords
myocardial infarction, glucose-insulin-potassium
Brief summary
The purpose of this study is: 1. to assess whether pre-hospital glucose-insulin-potassium (GIK) administration in acute STEMI patients would reduce infarct size and ischemia/reperfusion damage using comprehensive tissue characterization by cardiovascular magnetic resonance (CMR) at an early post-infarction phase. 2. to explore the putative cardioprotective mechanisms of pre-hospital GIK administration
Detailed description
Background - After an acute ST-segment elevation myocardial infarction (STEMI), early and successful myocardial reperfusion with primary percutaneous coronary intervention (PCI) is the most effective strategy for reducing the infarct size and improving clinical outcome. The process of restoring blood flow to the ischemic myocardium, however, can induce injury per se, paradoxically increasing the extent of final infarction (i.e., reperfusion injury). Research has been focusing for years on a strategy to effectively counteract reperfusion injury and, thereby, reduce the final infarct size with salutary effects on clinical outcome. Robust experimental evidences support Glucose-Insulin-Potassium (GIK) as an effective cardioprotective agent being capable to metabolically protect the myocardium against ischemia and ischemia/reperfusion injury. These benefits are clearly related to the time that GIK is administered in the course of cardiac ischemia, with effectiveness increasing with early administration. However, clinical trials in the reperfusion era have lost the opportunity to translate the beneficial effects seen in the laboratory to the clinical setting, because of the unacceptably prolonged delay from the onset of ischemic symptoms to GIK administration. A properly-designed prospective trial with double-blinded randomization to placebo or GIK in the out-of-hospital setting would straightforwardly overcome this limitation, thereby providing convincing evidences in favor or disfavor of GIK treatment. Notable, GIK is an un-expensive compound, and upon the verification of its efficacy, GIK treatment would be ready for primetime clinical application with matchless cost/effectiveness profile. Aims 1. to assess whether pre-hospital GIK administration in acute STEMI patients would reduce infarct size and ischemia/reperfusion damage using comprehensive tissue characterization by cardiovascular magnetic resonance (CMR) at an early post-infarction phase. 2. to explore the putative cardioprotective mechanisms of pre-hospital GIK administration Methods - The investigators will conduct a single-center randomized, placebo-controlled, double-blinded trial for testing the efficacy of pre-hospital GIK administration in patients with acutely reperfused STEMI. The pre-specified primary end-point is the reduction of infarct size, as quantitated by late gadolinium enhancement CMR in the early post-infarction phase. Major secondary end-points are: 1) reduction of ischemia/reperfusion injury quantitated by CMR, and 2) investigation of the putative cardioprotective mechanisms ofGIK treatment in subjects with acute STEMI. Outlook: The investigators study results, if positive, will persuade the scientific community to reconsider pre-hospital GIK treatment as adjunctive to primary PCI in acute STEMI patients and revitalize the field of metabolism-based cardioprotection. They will illustrate by which mechanisms cardioprotection is achieved in the clinical setting, prompting large prospective multicentre trials to test the efficacy of pre-hospital GIK administration on hard clinical end-points.
Interventions
Rackley's GIK formula by continuous I.V. infusion at 1.5 ml/Kg/hour for 12 hours (about 100 ml/hour for a 70 kg patient).
DRUGGlucose 5%
Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
Sponsors
Centre Hospitalier Universitaire Vaudois
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with the diagnosis of acute STEMI 2. age≥ 18 3. informed consent for study participation.
Exclusion criteria
evaluated during ambulance transport to primary PCI center: 1. end-stage renal failure requiring dialysis, 2. prior MI or coronary revascularization (PCI or CABG), 3. active malignances, 4. Pregnancy, 5. Hemodynamic instability (systolic blood pressure \<100mmHg or significant pulmonary congestion defined as O2 saturation \<90% on ambient air at pulso-oxymetry)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infarct size quantified by Late Gadolinium Enhancement using Cardiovascular Magnetic Resonance | 12 to 72 hours after the acute event |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The severity of ischemia/reperfusion injury (myocardial edema, microvascular obstruction and myocardial hemorrhage) | 12 to 72 hours after the acute event | The of ischemia/reperfusion injury will be assessed by multiparametric CMR |
| Major Adverse Cardiovascular Events | at 7-day, 30-day, 4-month and at 1-year follow-up | — |
| Post-infarction Remodeling | 4-month follow-up | Adverse post-infarction remodeling is defined as increase of LV end-systolic volume more than 15% between the first CMR (12 to 72 hours after the acute event) and second CMR (4-month after the acute event) |
Countries
Switzerland
Contacts
Primary ContactPier-Giorgio Masci, MD
Backup ContactJuerg Schwitter, MD
Outcome results
None listed